Call Us for Support
+91 9654860915
Google Reviews
4.8
Call Us for Support
+91 9654860915
Sourced directly from the authorized manufacturer network to ensure authenticity and quality.
Ready to proceed? Start a request for Bevifibatide on our secure patient portal to submit your prescription, upload documents and track your approval status.
Supplied with complete CDSCO-approved import and customs documentation, including Form 12A & 12B, CDEC, GST Bill of Entry, Commercial Invoice, and Packing List.
Manufacturer / Innovator:
China
Regulatory Approval:
Your Trustworthy Partner For Named Patient Program
Over a decade of trusted expertise in Named Patient Access to innovative and life-saving medicines.
100% CDSCO-compliant processes ensuring safe, ethical, and responsible medicine access.
Medicines sourced from authorized manufacturers with full batch traceability.
EU-GDP compliant warehousing for secure, quality-controlled global distribution.
Temperature-controlled logistics ensuring safe, reliable, and timely medicine delivery.
Bevifibatide is a short-acting, drip-fed blood thinner used during angioplasty for people with a heart attack or unstable angina. It was developed and is made in China by Bio-Thera Solutions, Ltd., and is sold there as 贝塔宁® (BETAGRIN®). It is given in the cath lab, around the time a narrowed heart artery is opened and stented, to stop clots forming on the fresh stent.
China's National Medical Products Administration (NMPA) approved it in 2024 (approval no. 国药准字H20240030) for:
It is a hospital-only heart medicine and is given only by an interventional cardiology team.
When an artery is ballooned and stented, platelets rush to the damaged spot and stick together. They do this through a receptor on their surface called GPIIb/IIIa (also known as αIIbβ3). Bevifibatide is a small ring-shaped peptide that sits on this receptor and stops fibrinogen and von Willebrand factor from binding, so platelets cannot clump into a clot. According to the Chinese label, it also blocks a related receptor, αvβ3, found on cells in the artery wall. In studies it blocked more than 80% of platelet clumping soon after the bolus, and platelet function returned quickly once the drip was stopped.
The approval rests on the phase 3 BES-PCI trial in China, which included 1,442 people with ACS having PCI (721 on bevifibatide and 721 on placebo, all also on standard antiplatelet treatment). Within 30 days, the combined rate of death, heart attack, urgent repeat procedure on the same artery, need for rescue anti-clot treatment, and no-reflow or severe slow-flow was 3.47% with bevifibatide against 5.83% with placebo. That is a 43% lower relative risk (hazard ratio 0.57, 95% CI 0.35–0.94, p = 0.026). The need for rescue anti-clot treatment fell from 1.66% to 0.28%.
The Chinese label sets the dose by body weight:
Each vial holds 20 mg in 10 mL. The bolus is drawn up undiluted; the infusion dose is diluted in saline to 240 mL and run at 10 mL per hour. As an example, from the label's dosing table a 70 kg adult needs 7.5 mL for the bolus and 122.4 mL for the infusion, or about 13 vials in total. Your cardiologist sets the exact plan.
This information is not a treatment plan. For personalized medical advice, consult your doctor and refer to the full prescribing information.
Bleeding: this is the most common problem, as with any medicine that stops platelets sticking. In the phase 3 trial, bleeding of any kind occurred in 7.88% of people on bevifibatide against 4.57% on placebo. Most of it was minimal (5.39%) or minor (2.21%), mainly from the gums, the puncture site, the gut or the urinary tract. Major bleeding occurred in 0.28% (2 people), and one person (0.14%) had a bleed in the brain. No one needed a transfusion for bleeding linked to the medicine. If bleeding cannot be controlled with pressure, the drip is stopped straight away.
Who should not receive it: people with a bleeding tendency or active bleeding in the past 30 days; very high blood pressure that is not controlled (above 200/110 mmHg); major surgery in the past 6 weeks; a past bleeding stroke, or any stroke in the past 30 days; a brain tumour, aneurysm or AV malformation; platelets below 100,000/mm³; a clotting disorder (INR above 2); severe liver failure; or a known allergy to any ingredient.
In the trial, 1.24% stopped treatment because of side effects, against 1.11% on placebo. Older patients had more bleeding than younger ones, but no dose change is needed. It has not been properly studied in pregnancy, and safety in children has not been established.
Step 1 – Search & request your medicine: The patient or treating doctor submits a request with basic details to initiate the access process.
Step 2 – Verification & eligibility review: The team verifies availability and reviews eligibility against regulatory and clinical requirements to ensure a compliant pathway.
Step 3 – Receive quote & delivery timeline: A transparent quotation is shared, covering medicine cost, logistics, and a clear delivery timeline.
Step 4 – Regulatory approval process: Assistance is provided to secure the approvals and documentation required for legal cross-border access.
Step 5 – Temperature-controlled import & handling: The medicine is sourced and transported under strict GDP-compliant, cold-chain conditions to maintain product integrity.
Step 6 – Secure delivery: The medicine is delivered to the patient or treating hospital, with updates provided at each stage.
Note: From request to delivery, every step is designed to ensure your treatment reaches you safely, compliantly, and without unnecessary delays.
The injection can be imported only in the patient's name, by the patient or a government hospital, in line with India's import regulations for unapproved medicines. You will need:
Once we have received and checked a valid prescription and, where needed, an import permit.
No. It is approved only in China. It has no CDSCO approval, it is not sold in Indian pharmacies, and the US FDA and European Medicines Agency have not approved it either.
Patients can still get it legally through the Named Patient Program (NPP), which allows a medicine not registered in India to be imported for one specific patient on a prescription. Because it is used around a planned procedure, the hospital team should contact us well before the PCI date so the import can be completed in time.
It can be made available to patients, doctors, and hospitals across major cities in India, including Gurgaon, Delhi, Bangalore, Mumbai, Navi Mumbai, Thane, Hyderabad, Mysore, Kerala, Chennai, Coimbatore, Madurai, Kolkata, Ahmedabad, Surat, Vadodara, Pune, Nagpur, Nashik, Jaipur, Udaipur, Lucknow, Kanpur, Gorakhpur, Chandigarh, Mohali, Faridabad, Noida, Ghaziabad, Kochi, Trivandrum, Kozhikode, Thrissur, Kannur, Mangalore, Bhubaneswar, Patna, Ranchi, Raipur, Guwahati, Visakhapatnam, Vijayawada, Goa, Jammu, Srinagar, Dehradun, Bhopal, Indore, Ludhiana, Amritsar, and others — and can facilitate delivery to the patient's treating hospital. Orders are confirmed only after receipt of a valid doctor's prescription and an import permit, where applicable.
NamedPatientProgram.com (NPP) sources this medicine through the manufacturer's authorised supply channels in China and arranges supply to patients, doctors, and hospitals under applicable legal provisions. The vials must be kept at 2°C to 8°C, sealed and away from light, so they travel under temperature-controlled shipping all the way to the hospital pharmacy. The number of vials depends on body weight, so we confirm the quantity with the treating team before ordering. All prescriptions are dispensed and checked by registered pharmacists and dispatched from New Delhi, India, after legal requirements are fulfilled.
For the current cost in India and availability, contact NPP via WhatsApp at +91 98104 69557 | Toll-Free: 1800-1200-365 or email info@namedpatientprogram.com.
Patients across India can access this medicine through regulated import pathways, with delivery arranged to the treating hospital on a valid specialist's prescription.
Cath labs in Delhi handle heart attack cases from across North India, and our New Delhi dispatch point keeps the refrigerated journey short.
Vials are delivered to the hospital pharmacy so they are ready before the planned angioplasty.
Interventional cardiologists in Bangalore can request the medicine for a named patient, with the quote shared before anything is ordered.
A major centre for cardiac procedures in South India, with experience in storing imported medicines at 2°C to 8°C.
We confirm the patient's weight and the number of vials with the cardiology team before dispatch.
Shipments to Kolkata and the eastern states are packed to stay within 2°C to 8°C throughout.
Hospitals in Pune can use the same documented import route, with updates at each stage.
The treating cardiologist can send us the prescription and procedure details to begin the import.
Patients in Rajasthan can have the vials delivered directly to their treating heart hospital.
Serves patients from Punjab, Haryana and Himachal Pradesh, with delivery to the treating hospital.
We coordinate cold-chain delivery to public and private heart hospitals across Uttar Pradesh.
Patients across Kerala can receive the medicine at their hospital in Kochi and nearby cities.
Access can also be coordinated for patients in other Indian cities, subject to a valid prescription and regulatory requirements.
Written By
Nitin GoswamiDeputy Manager – Content & Social Media, Ikris Pharma Network
Sources: NMPA • CDSCO
Last Updated: 19 October 2026
Our specialists are here to guide you through every step of the medicine access process.
Mail Us At:
info@namedpatientprogram.comContact Us:
+91 9654860915Send us a message
